Suven Life gets five patent approvals for CNS molecules

Drug firm Suven Life Sciences  today said it has received five product patents, three from China and two from Korea for its new chemical entities (NCEs), which could be used for treating various central nervous system disorders.

The product patents are valid through 2027 and 2028 respectively, Suven Life Sciences said in a filing to the BSE. The company has received approval for molecules that could be used in the treatment of neurodegenerative disorders like Parkinson's, Alzheimer's and Schizophrenia, it added.

Products developed out of these molecules may be out-licensed at various phases of clinical development like Phase I or Phase II, the company said.

Commenting on the development, Suven CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."

With these new patents, the company now has a total of eight patents from China and ten patents from Korea, the company said. Shares of Suven Life Sciences were trading at Rs 33.80 on the BSE in afternoon trade, up 2.11 percent from previous close.